407:(CNHD) from healthy patients, with 94% sensitivity and 97% specificity. An NT-proBNP value of 408 pg/mL has been estimated to be 83% sensitive and 57% specific in differentiating patients with ACNHD from patients with CNHD. In patients with non-severe asymptomatic aortic valve stenosis, increased age- and sex adjusted NT-proBNP levels alone and combined with a 50% or greater increase from baseline had been found associated with increased event rates of
204:(CHF) and may be useful to establish prognosis in heart failure, as both markers are typically higher in patients with worse outcome. The plasma concentrations of both BNP and NT-proBNP are also typically increased in patients with asymptomatic or symptomatic left ventricular dysfunction and is associated with
460:
industry to screen applicants as part of the routine requirements when applying for a life insurance policy. It is also inexpensive and can be measured from blood samples routinely drawn as part of the application process. The test can be used to evaluate for a number of health conditions.
531:
Atisha D, Bhalla MA, Morrison LK, Felicio L, Clopton P, Gardetto N, et al. (September 2004). "A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction".
698:
Ruwald MH, Goetze JP, Bech J, Nielsen OW, Madsen BK, Nielsen LB, et al. (January 2014). "NT-ProBNP independently predicts long-term mortality in patients admitted for coronary angiography".
927:"Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial"
746:"Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial"
57:
404:
569:"Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy"
1117:
Clark M, Kaufman V, Fulks M, Dolan VF, Stout RL (2014). "NT-proBNP as a predictor of all-cause mortality in a population of insurance applicants".
801:
894:"Usefulness of N-Terminal-Pro-B-Type Natriuretic Peptide as a Screening Tool for Identifying Pediatric Patients With Congenital Heart Disease"
830:
1163:
81:
444:
While discussed in
Canadian medical journals in the mid to late 2000s, the test is not widely used. It was only approved for use in
974:
Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder T, Pacher R, Maurer G, Baumgartner H (2004-05-18).
228:
69:
62:
247:
659:"Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome"
1089:
1062:
194:
400:
396:
403:
of 42%. On the other hand, an NT-proBNP cut-off value of 318 pg/mL is more appropriate in differing patients with
1173:
470:
50:
35:
420:
388:
355:
201:
392:
205:
492:"B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure"
74:
1023:"Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea"
976:"Natriuretic Peptides Predict Symptom-Free Survival and Postoperative Outcome in Severe Aortic Stenosis"
793:
925:
Hadziselimovic E, Greve AM, Sajadieh A, Olsen MH, Kesäniemi YA, Nienaber CA, et al. (April 2022).
744:
Hadziselimovic E, Greve AM, Sajadieh A, Olsen MH, Kesäniemi YA, Nienaber CA, et al. (April 2022).
1090:"NT-proBNP The Finest Cardiovascular Screening and Reflexive Test In the History of Life Underwriting"
975:
127:
1168:
610:"Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina"
209:
723:
1148:
1126:
1044:
1003:
995:
956:
869:
826:
820:
775:
715:
680:
639:
590:
549:
513:
848:"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure"
846:
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. (July 2002).
1034:
987:
946:
938:
905:
859:
765:
757:
707:
670:
629:
621:
580:
541:
503:
428:
122:
384:
There is no level of BNP that perfectly separates patients with and without heart failure.
131:
424:
408:
213:
151:
567:
Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, et al. (May 2002).
991:
951:
926:
770:
745:
634:
609:
457:
585:
568:
200:
Both BNP and NT-proBNP levels in the blood are used for screening, diagnosis of acute
1157:
508:
491:
416:
412:
391:
in pediatric patients, an NT-proBNP cut-off value of 91 pg/mL could differentiate an
727:
942:
761:
98:
161:
1066:
1039:
1022:
545:
190:
186:
105:
999:
910:
893:
711:
367:
361:
1130:
1048:
1007:
960:
873:
779:
719:
684:
657:
Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. (November 2006).
643:
625:
594:
553:
517:
675:
658:
864:
847:
427:, NT-proBNP provide important prognostic information beyond clinical and
110:
17:
800:. The University of Iowa (UIHC), Department of Pathology. 28 May 2020.
445:
1063:"B-type Natriuretic Peptide (BNP) & NT-proBNP Test Implementation"
93:
608:
Talwar S, Squire IB, Downie PF, Davies JE, Ng LL (October 2000).
86:
892:
Moses EJ, Mokhtar SA, Hamzah A, Abdullah BS, Yusoff NM (2011).
193:
inactive protein that is cleaved from the molecule to release
1021:
Murray H, Cload B, Collier CP, Sivilotti ML (July 2006).
223:
340:
157:
147:
142:
121:
116:
104:
92:
80:
68:
56:
46:
41:
34:
175:N-terminal prohormone of brain natriuretic peptide
197:(BNP, also known as B-type natriuretic peptide).
806:Showing 95th percentiles. Epic Lab Code: LAB649.
419:due to progression of aortic valve stenosis, or
395:(ACNHD) patient from a healthy patient with a
573:Journal of the American College of Cardiology
229:Upper limit (95th percentile) of blood ranges
8:
887:
885:
883:
822:Basic Skills in Interpreting Laboratory Data
405:congenital nonspherocytic hemolytic disease
825:. Amer Soc of Health System. p. 220.
814:
812:
139:
1065:. Alberta Health Services. Archived from
1038:
950:
909:
863:
769:
674:
633:
584:
507:
452:Test usage in the life insurance industry
482:
490:Bhalla V, Willis S, Maisel AS (2004).
31:
456:The test has been widely used in the
7:
739:
737:
852:The New England Journal of Medicine
992:10.1161/01.CIR.0000126825.50903.18
25:
804:from the original on 2008-10-11.
509:10.1111/j.1527-5299.2004.03310.x
435:Test usage in a clinical setting
232:for NT-proBNP in healthy people
1:
1119:Journal of Insurance Medicine
586:10.1016/s0735-1097(02)01813-2
943:10.1001/jamacardio.2021.5916
798:LABORATORY SERVICES HANDBOOK
762:10.1001/jamacardio.2021.5916
195:brain natriuretic peptide 32
1164:Genes on human chromosome 1
1190:
1040:10.1017/s1481803500013798
546:10.1016/j.ahj.2004.03.014
471:Brain natriuretic peptide
354:
296:
253:
226:
138:
911:10.1309/LMW0U87COTHXGELF
712:10.1177/0003319712462758
496:Congestive Heart Failure
421:aortic valve replacement
389:congenital heart disease
356:Congestive heart failure
202:congestive heart failure
415:, hospitalization with
393:acyanotic heart disease
206:coronary artery disease
626:10.1136/heart.84.4.421
534:American Heart Journal
27:Precursor of a hormone
1147:BNP and NT-proBNP at
676:10.1253/circj.70.1379
425:aortic valve stenosis
409:aortic valve stenosis
214:aortic valve stenosis
189:with a 76 amino acid
36:natriuretic peptide B
865:10.1056/NEJMoa020233
794:"N-terminal-pro-BNP"
423:surgery). In severe
413:cardiovascular death
898:Laboratory Medicine
663:Circulation Journal
502:(1 Suppl 1): 3–27.
210:myocardial ischemia
448:in February 2012.
212:, and severity of
1088:George H (2010).
986:(19): 2302–2308.
832:978-1-58528-180-0
669:(11): 1379–1384.
579:(10): 1657–1663.
429:echocardiographic
387:In screening for
382:
381:
339:
338:
171:
170:
167:
166:
16:(Redirected from
1181:
1174:Peptide hormones
1149:Lab Tests Online
1135:
1134:
1114:
1108:
1107:
1105:
1103:
1094:
1085:
1079:
1078:
1076:
1074:
1069:on 22 April 2015
1059:
1053:
1052:
1042:
1018:
1012:
1011:
971:
965:
964:
954:
922:
916:
915:
913:
889:
878:
877:
867:
843:
837:
836:
816:
807:
805:
790:
784:
783:
773:
741:
732:
731:
695:
689:
688:
678:
654:
648:
647:
637:
605:
599:
598:
588:
564:
558:
557:
528:
522:
521:
511:
487:
411:related events (
341:
224:
140:
32:
21:
1189:
1188:
1184:
1183:
1182:
1180:
1179:
1178:
1154:
1153:
1144:
1139:
1138:
1116:
1115:
1111:
1101:
1099:
1092:
1087:
1086:
1082:
1072:
1070:
1061:
1060:
1056:
1020:
1019:
1015:
973:
972:
968:
931:JAMA Cardiology
924:
923:
919:
891:
890:
881:
845:
844:
840:
833:
819:Lee MA (2009).
818:
817:
810:
792:
791:
787:
750:JAMA Cardiology
743:
742:
735:
697:
696:
692:
656:
655:
651:
607:
606:
602:
566:
565:
561:
530:
529:
525:
489:
488:
484:
479:
467:
454:
442:
437:
245:
231:
222:
28:
23:
22:
15:
12:
11:
5:
1187:
1185:
1177:
1176:
1171:
1166:
1156:
1155:
1152:
1151:
1143:
1142:External links
1140:
1137:
1136:
1109:
1080:
1054:
1033:(4): 251–258.
1013:
966:
937:(4): 435–444.
917:
879:
858:(3): 161–167.
838:
831:
808:
785:
756:(4): 435–444.
733:
690:
649:
620:(4): 421–424.
600:
559:
540:(3): 518–523.
523:
481:
480:
478:
475:
474:
473:
466:
463:
458:life insurance
453:
450:
441:
438:
436:
433:
380:
379:
376:
372:
371:
365:
359:
352:
351:
348:
345:
344:Interpretation
337:
336:
333:
329:
328:
325:
321:
320:
317:
313:
312:
309:
305:
304:
301:
298:
294:
293:
290:
286:
285:
282:
278:
277:
274:
270:
269:
266:
262:
261:
258:
255:
251:
250:
242:
239:
235:
234:
221:
218:
169:
168:
165:
164:
159:
155:
154:
149:
145:
144:
136:
135:
125:
119:
118:
114:
113:
108:
102:
101:
96:
90:
89:
84:
78:
77:
72:
66:
65:
60:
54:
53:
48:
44:
43:
39:
38:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1186:
1175:
1172:
1170:
1167:
1165:
1162:
1161:
1159:
1150:
1146:
1145:
1141:
1132:
1128:
1124:
1120:
1113:
1110:
1098:
1091:
1084:
1081:
1068:
1064:
1058:
1055:
1050:
1046:
1041:
1036:
1032:
1028:
1024:
1017:
1014:
1009:
1005:
1001:
997:
993:
989:
985:
981:
977:
970:
967:
962:
958:
953:
948:
944:
940:
936:
932:
928:
921:
918:
912:
907:
903:
899:
895:
888:
886:
884:
880:
875:
871:
866:
861:
857:
853:
849:
842:
839:
834:
828:
824:
823:
815:
813:
809:
803:
799:
795:
789:
786:
781:
777:
772:
767:
763:
759:
755:
751:
747:
740:
738:
734:
729:
725:
721:
717:
713:
709:
705:
701:
694:
691:
686:
682:
677:
672:
668:
664:
660:
653:
650:
645:
641:
636:
631:
627:
623:
619:
615:
611:
604:
601:
596:
592:
587:
582:
578:
574:
570:
563:
560:
555:
551:
547:
543:
539:
535:
527:
524:
519:
515:
510:
505:
501:
497:
493:
486:
483:
476:
472:
469:
468:
464:
462:
459:
451:
449:
447:
439:
434:
432:
430:
426:
422:
418:
417:heart failure
414:
410:
406:
402:
398:
394:
390:
385:
378:>450pg/mL
377:
374:
373:
369:
366:
363:
360:
357:
353:
349:
346:
343:
342:
334:
331:
330:
326:
323:
322:
318:
315:
314:
310:
307:
306:
302:
299:
295:
291:
288:
287:
283:
280:
279:
275:
272:
271:
267:
264:
263:
259:
256:
252:
249:
243:
240:
237:
236:
233:
230:
225:
219:
217:
215:
211:
207:
203:
198:
196:
192:
188:
184:
180:
176:
163:
160:
156:
153:
150:
146:
141:
137:
134:
133:
129:
126:
124:
120:
115:
112:
109:
107:
103:
100:
97:
95:
91:
88:
85:
83:
79:
76:
73:
71:
67:
64:
61:
59:
55:
52:
49:
45:
40:
37:
33:
30:
19:
1122:
1118:
1112:
1100:. Retrieved
1097:Insureintell
1096:
1083:
1071:. Retrieved
1067:the original
1057:
1030:
1026:
1016:
983:
979:
969:
934:
930:
920:
904:(2): 75–80.
901:
897:
855:
851:
841:
821:
797:
788:
753:
749:
706:(1): 31–36.
703:
699:
693:
666:
662:
652:
617:
613:
603:
576:
572:
562:
537:
533:
526:
499:
495:
485:
455:
443:
431:evaluation.
386:
383:
375:>75 years
227:
220:Blood levels
199:
182:
178:
174:
172:
130:
29:
1125:(1): 7–16.
980:Circulation
401:specificity
399:of 84% and
397:sensitivity
332:> 75 yrs
289:> 75 yrs
152:Swiss-model
42:Identifiers
1169:Biomarkers
1158:Categories
477:References
370:125 pg/mL
191:N-terminal
187:prohormone
148:Structures
143:Search for
117:Other data
1073:3 January
1000:0009-7322
700:Angiology
324:65-74 yrs
316:55-64 yrs
308:45-54 yrs
300:19-44 yrs
281:65-74 yrs
273:55-64 yrs
265:45-54 yrs
257:19-44 yrs
179:NT-proBNP
99:NM_002521
58:NCBI gene
18:NT-proBNP
1131:25004594
1049:17324304
1008:15117847
961:35171199
874:12124404
802:Archived
780:35171199
728:33475819
720:23070682
685:17062957
644:10995414
595:12020494
554:15389242
518:14872150
465:See also
364:75 years
162:InterPro
1102:11 July
952:8851368
771:8851368
635:1729429
446:Alberta
297:Females
185:) is a
158:Domains
106:UniProt
1129:
1047:
1006:
998:
959:
949:
872:
829:
778:
768:
726:
718:
683:
642:
632:
593:
552:
516:
440:Canada
358:likely
350:Range
244:Limit
128:Chr. 1
111:P16860
94:RefSeq
87:600295
47:Symbol
1093:(PDF)
724:S2CID
614:Heart
248:pg/mL
132:p36.2
123:Locus
1127:PMID
1104:2016
1075:2013
1045:PMID
1027:CJEM
1004:PMID
996:ISSN
957:PMID
870:PMID
827:ISBN
776:PMID
716:PMID
681:PMID
640:PMID
591:PMID
550:PMID
514:PMID
368:>
362:<
335:624
327:353
319:226
311:192
303:178
292:852
284:229
276:177
268:138
254:Male
183:BNPT
173:The
82:OMIM
75:7940
70:HGNC
63:4879
51:NPPB
1035:doi
988:doi
984:109
947:PMC
939:doi
906:doi
860:doi
856:347
766:PMC
758:doi
708:doi
671:doi
630:PMC
622:doi
581:doi
542:doi
538:148
504:doi
347:Age
260:93
246:in
241:Age
238:Sex
181:or
1160::
1123:44
1121:.
1095:.
1043:.
1029:.
1025:.
1002:.
994:.
982:.
978:.
955:.
945:.
933:.
929:.
902:42
900:.
896:.
882:^
868:.
854:.
850:.
811:^
796:.
774:.
764:.
752:.
748:.
736:^
722:.
714:.
704:65
702:.
679:.
667:70
665:.
661:.
638:.
628:.
618:84
616:.
612:.
589:.
577:39
575:.
571:.
548:.
536:.
512:.
500:10
498:.
494:.
216:.
208:,
1133:.
1106:.
1077:.
1051:.
1037::
1031:8
1010:.
990::
963:.
941::
935:7
914:.
908::
876:.
862::
835:.
782:.
760::
754:7
730:.
710::
687:.
673::
646:.
624::
597:.
583::
556:.
544::
520:.
506::
177:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.